2026 ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE • ORLANDO, FL
The following press release was obtained from BridgeBio.com, parent company of QED therapeutics. To learn more about QED and their research surrounding achondroplasia and other skeletal dysplasias, click here. – Treatment with infigratinib at…
The following press release was obtained from BridgeBio.com, parent company of QED therapeutics. To learn more about QED and their research surrounding achondroplasia and other skeletal dysplasias, click here. PALO ALTO, Calif., June…
In the highest dose level (Cohort 5, 0.25 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) at six months was +3.03 cm/yr (p = 0.0022)…
PRESS RELEASE OBTAINED FROM BRIDGEBIO SITE – INVESTOR.BRIDGEBIO.COM – At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline in annualized…
